CN113679046B - Composition for promoting interaction of hyaluronic acid and collagen and application thereof - Google Patents
Composition for promoting interaction of hyaluronic acid and collagen and application thereof Download PDFInfo
- Publication number
- CN113679046B CN113679046B CN202110963198.3A CN202110963198A CN113679046B CN 113679046 B CN113679046 B CN 113679046B CN 202110963198 A CN202110963198 A CN 202110963198A CN 113679046 B CN113679046 B CN 113679046B
- Authority
- CN
- China
- Prior art keywords
- collagen
- hyaluronic acid
- composition
- parts
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 100
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 100
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 100
- 102000008186 Collagen Human genes 0.000 title claims abstract description 93
- 108010035532 Collagen Proteins 0.000 title claims abstract description 93
- 229920001436 collagen Polymers 0.000 title claims abstract description 93
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 230000001737 promoting effect Effects 0.000 title abstract description 12
- 230000003993 interaction Effects 0.000 title abstract description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 59
- 229940124277 aminobutyric acid Drugs 0.000 claims abstract description 40
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 239000002537 cosmetic Substances 0.000 claims abstract description 19
- 102000015636 Oligopeptides Human genes 0.000 claims description 10
- 108010038807 Oligopeptides Proteins 0.000 claims description 10
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 9
- 102000012422 Collagen Type I Human genes 0.000 claims description 9
- 108010022452 Collagen Type I Proteins 0.000 claims description 9
- 229940014041 hyaluronate Drugs 0.000 claims description 9
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 7
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 7
- 102000000503 Collagen Type II Human genes 0.000 claims description 6
- 108010041390 Collagen Type II Proteins 0.000 claims description 6
- 102000001187 Collagen Type III Human genes 0.000 claims description 5
- 108010069502 Collagen Type III Proteins 0.000 claims description 5
- 102000012432 Collagen Type V Human genes 0.000 claims description 5
- 108010022514 Collagen Type V Proteins 0.000 claims description 5
- 102000009736 Collagen Type XI Human genes 0.000 claims description 5
- 108010034789 Collagen Type XI Proteins 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940127557 pharmaceutical product Drugs 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- VJVOFLWZDWLHNR-MRCUWXFGSA-N icosan-9-yl (z)-docos-13-enoate Chemical compound CCCCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VJVOFLWZDWLHNR-MRCUWXFGSA-N 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229960003975 potassium Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 24
- 230000015572 biosynthetic process Effects 0.000 abstract description 19
- 238000003786 synthesis reaction Methods 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 229960005188 collagen Drugs 0.000 description 80
- 210000003491 skin Anatomy 0.000 description 18
- 210000002950 fibroblast Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 210000001626 skin fibroblast Anatomy 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000008845 photoaging Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000962514 Alosa chrysochloris Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 1
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 1
- 101710197056 Hyaluronan synthase 2 Proteins 0.000 description 1
- 102100040206 Hyaluronan synthase 2 Human genes 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000006571 energy metabolism pathway Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000004520 water soluble gel Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition for doubly promoting interaction of hyaluronic acid and collagen and application thereof. The composition of the present invention comprises hyaluronic acid or a salt thereof, collagen and aminobutyric acid. According to the composition disclosed by the invention, hyaluronic acid and collagen can interact to promote the self synthesis of substances, and aminobutyric acid can promote the respective synthesis of hyaluronic acid and collagen, so that the aminobutyric acid is added into the composition formed by hyaluronic acid and collagen, the purpose of synergy is achieved while the respective effects are kept, the synthesis efficiency of hyaluronic acid and collagen can be doubly promoted, the effect of reducing and synergy is achieved, the cost and the use risk are reduced, the application range and the safety are expanded, and the composition has a good application prospect in the fields of foods, cosmetics or medicines.
Description
Technical Field
The invention relates to the technical field of foods, cosmetics or medicines, in particular to a composition for doubly promoting interaction of hyaluronic acid and collagen and application thereof.
Background
Hyaluronic Acid (HA) is a high molecular mucopolysaccharide with N-acetylglucosamine and D-glucuronic acid as structural units, and HAs unique molecular structure and physicochemical properties, thus exhibiting various important physiological functions in human body, such as lubricating joints, regulating permeability of vascular wall, regulating diffusion and operation of protein, water and electrolyte, promoting wound healing, etc. Hyaluronic acid is added into health food, and can be used for oral administration, and has obvious effects of caring skin and promoting health. The oral cosmetic health product containing hyaluronic acid has systemic effect, and is prepared by increasing endogenous hyaluronic acid content from dermis to epidermis, activating cells, and performing systemic effect, which is obviously different from topical cosmetic application. The beauty of the surface mainly considers the care of the epidermis, while the main component of the skin is dermis, which is mainly composed of collagen, and as the age increases, the aging of the skin is caused by the decrease of collagen, and the amount of collagen is closely related to the amount of hyaluronic acid with water retention.
Collagen (Collagen) is a biological polymer, is a spiral fibrous protein composed of 3 peptide chains, is a structural protein of extracellular matrix, and 70% of subcutaneous dermal tissue is composed of Collagen, thus being the protein with the most abundant content in human body. Collagen, which is about 30% of the total protein content of the human body and corresponds to 6% of the weight of the human body, is a main component for maintaining the morphology and structure of the skin and tissue organs throughout the whole body, and is an important raw material for repairing damaged tissues. And is also a substance for keeping the body young and preventing aging. In addition, the collagen can also prevent diseases, improve physique and greatly help beauty and health.
Aminobutyric acid (gamma-aminobutyric acid, GABA) is a small molecular weight non-protein amino acid widely distributed in animals and plants, is an inhibitory transmitter of the central nervous system, is one of the most important neurotransmitters in brain tissues, and has the effects of reducing neuron activity, inhibiting anxiety information from being transmitted into the brain center of a human body, tranquilizing nerves, resisting anxiety, resisting skin aging and the like.
Hyaluronic acid and collagen are commonly used as raw material substances in the fields of food, cosmetics and medicines, have synergistic and mutual synthesis promotion effects, and the interaction mechanism is that after the hyaluronic acid enters human cells, the expression of type I and type III collagen mRNA can be promoted to be up-regulated, so that the collagen synthesis can be increased. Collagen can promote mRNA level elevation by promoting human skin fibroblast FB mitosis, proliferation and activating transcription of hyaluronic acid synthase 2 (Hyaluronic AcidSynthetase II, HAS 2), thereby promoting synthesis of hyaluronic acid.
The deer collagen nutritional composition of the patent CN103768585B provides a nutritional composition which takes deer collagen as a main component and is supplemented with glucosamine, hyaluronic acid, soy isoflavone and tea polyphenol with antioxidation, so that the nutritional composition can strengthen bone density and can remarkably improve osteoporosis.
The patent application CN108201523A provides a moisturizing and whitening essence containing collagen, and a essence product consisting of plant extracts, collagen, hyaluronic acid, glycerol and deionized water, and has the effects of resisting aging, moisturizing, whitening and the like.
The aminobutyric acid serving as an emerging raw material not only can be applied to the field of medicines, but also is increasingly prominent in the fields of foods and cosmetics. Besides the tranquilizing and allaying excitement effect, the collagen-hyaluronic acid gel has the effect of enhancing the synthesis of hyaluronic acid and collagen. The mechanism of the aminobutyric acid for promoting the synthesis of hyaluronic acid is as follows: aminobutyric acid can improve survival rate of fibroblasts, stimulate fibroblasts, participate in proliferation and division of fibroblasts, and the fibroblasts have the characteristic of producing Extra Cell Matrix (ECM), namely hyaluronic acid, elastin, collagen and the like. The mechanism of the aminobutyric acid for promoting collagen synthesis is a receptor-mediated mechanism, and the aminobutyric acid can control the activity of fibroblasts, and can remarkably increase the expression of a protoelastase transcript and the formation of elastic fibers in the fibroblasts. And it can be metabolized by fibroblasts, participating in the energy metabolic pathways of the cells. The synergistic application of three substances of aminobutyric acid, hyaluronic acid and collagen in the market is mainly based on two-by-two combination.
The patent CN105362091B provides a composition containing gamma-aminobutyric acid and hyaluronic acid and application thereof in cosmetics, comprising gamma-aminobutyric acid and hyaluronic acid or salts thereof, which can remarkably improve and reduce adverse reactions of gamma-aminobutyric acid to skin, overcome the stimulation of the gamma-aminobutyric acid to the skin by singly using the gamma-aminobutyric acid, improve the content of the gamma-aminobutyric acid in the cosmetics, and can quickly remove wrinkles, supplement water for a long time and enable the skin to be youthful.
The collagen powder for helping sleep in the patent application CN109953348A provides a composition with the effects of stabilizing spirit and calming, can remarkably improve the sleeping condition, and is particularly suitable for people with poor sleeping condition.
The collagen ceramide drink of the patent CN103719995B provides a drink containing collagen, ceramide, gamma-aminobutyric acid and vitamin C, can act on the cuticle and dermis of the skin, supplement the collagen and the ceramide, can relieve pressure, and has the effect of remarkably improving skin moisture.
The application CN106723000A provides a skipjack elastin peptide, a fish collagen peptide and gamma aminobutyric acid composition, which can improve the moisture content, the hyaluronic acid content and the collagen content of skin.
The three are applied together in few examples, and most of the applications only use the respective properties of the three substances, and the dual addition effect of the aminobutyric acid on the synergy of the hyaluronic acid and the collagen is not reflected.
Disclosure of Invention
In order to solve the problems, the invention provides a composition for doubly promoting interaction between hyaluronic acid and collagen, which takes aminobutyric acid as an accelerator to enhance synergistic effect of the hyaluronic acid and the collagen. And through adjusting the dosage proportion of aminobutyric acid, hyaluronic acid and collagen, the synergistic interaction effect can be achieved, the dosage of hyaluronic acid and collagen can be reduced on the premise of keeping the original active efficacy, the cost is reduced, and the risk caused by too high dosage is reduced.
The specific technical scheme of the invention is as follows:
1. a composition comprising hyaluronic acid or a salt thereof, collagen, and aminobutyric acid.
2. The composition according to item 1, wherein the hyaluronic acid or salt thereof is selected from hyaluronic acid, sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, calcium hyaluronate, magnesium hyaluronate, acetylated hyaluronic acid, thiolated hyaluronic acid or lightly crosslinked hyaluronic acid, preferably sodium hyaluronate.
3. The composition according to claim 1 or 2, wherein the collagen is selected from the group consisting of type i collagen, type ii collagen, type iii collagen, type v collagen, type xi collagen or an oligopeptide thereof, preferably type i collagen.
4. The composition according to any one of claims 1 to 3, wherein the hyaluronic acid or a salt thereof is 1 to 100 parts by weight, preferably 10 to 100 parts by weight, further preferably 50 to 100 parts by weight;
the collagen is 100-10000 parts, preferably 1000-10000 parts, more preferably 5000-10000 parts;
the aminobutyric acid is 1 to 100 parts, preferably 10 to 100 parts, and more preferably 50 to 100 parts.
5. The composition according to any one of claims 1 to 4, wherein the hyaluronic acid or salt thereof has a molecular weight of 10k-1000kDa, preferably 10k-100kDa or 200k-800kDa, further preferably 30k-50kDa or 200k-400kDa.
6. The composition according to any one of claims 1 to 5, wherein the collagen has a molecular weight of 200-10000Da, preferably 300-5000Da, more preferably 500-2000Da.
7. An article comprising the composition of any one of claims 1-6, wherein the composition is 0.1-10%, preferably 1-5% by mass of the article.
8. The article of claim 7, wherein the article is a food, cosmetic or pharmaceutical product.
9. The article of claim 8, wherein the article further comprises an adjunct, preferably, the adjunct is a food, cosmetic or pharmaceutical acceptable adjunct.
10. The article of claim 8 or 9, wherein the food product is a health food product.
11. Use of the composition of any one of items 1 to 6 in the field of food, cosmetics or pharmaceuticals.
12. The use according to item 11, wherein the food is a health food.
ADVANTAGEOUS EFFECTS OF INVENTION
According to the composition provided by the invention, hyaluronic acid and collagen can interact to promote the self synthesis of substances, and aminobutyric acid can promote the respective synthesis of hyaluronic acid and collagen, so that the aminobutyric acid is added into the composition formed by hyaluronic acid and collagen, the purpose of synergy is achieved while the respective effects are kept, the synthesis efficiency of hyaluronic acid and collagen can be doubly promoted, the effect of reducing and synergy is achieved, the cost and the use risk are reduced, the application range and the safety are expanded, and the composition has good application prospects in the fields of foods, cosmetics or medicines.
Detailed Description
The present invention will be described in detail below. While specific embodiments of the invention are shown, it should be understood that the invention may be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
It should be noted that certain terms are used throughout the description and claims to refer to particular components. Those of skill in the art will understand that a person may refer to the same component by different names. The specification and claims do not identify differences in terms of components, but rather differences in terms of the functionality of the components. As referred to throughout the specification and claims, the terms "include" or "comprising" are used in an open-ended fashion, and thus should be interpreted to mean "include, but not limited to. The description hereinafter sets forth a preferred embodiment for practicing the invention, but is not intended to limit the scope of the invention, as the description proceeds with reference to the general principles of the description. The scope of the invention is defined by the appended claims.
The present invention provides a composition comprising hyaluronic acid or a salt thereof, collagen, and aminobutyric acid.
In a preferred embodiment of the present invention, wherein the hyaluronic acid or salt thereof is selected from the group consisting of hyaluronic acid, sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, calcium hyaluronate, magnesium hyaluronate, acetylated hyaluronic acid, thiolated hyaluronic acid or lightly crosslinked hyaluronic acid, preferably sodium hyaluronate.
The acetylated hyaluronic acid is obtained by acetylation reaction of sodium hyaluronate.
The sulfhydrylation hyaluronic acid refers to sulfhydrylation modified hyaluronic acid, namely, the sulfhydrylation hyaluronic acid is prepared by taking the hyaluronic acid as a raw material, introducing disulfide bonds through an activated carboxyl band, and then reducing the disulfide bonds into sulfhydrylation.
The slightly crosslinked hyaluronic acid refers to a high molecular water-soluble gel with a three-dimensional structure, which is obtained by crosslinking and modifying hyaluronic acid by a crosslinking agent.
In a preferred embodiment of the present invention, the collagen is selected from the group consisting of type i collagen, type ii collagen, type iii collagen, type v collagen, type xi collagen and oligopeptides thereof, preferably type i collagen.
The type I collagen is the most abundant collagen in the human body. It forms large eosinophilic fibers, called collagen fibers. It is present in scar tissue and tissue healing at the end product is through repair, as well as tendons, ligaments, organic parts of the bones of the myofibrils of the intima, in the dermis, dentin and organ capsules.
The type II collagen is a naturally occurring protein, which is present in hyaline cartilage and articular cartilage of the human body.
The type III collagen is the main collagen in human skin, fascia and tendon, is homotrimer or is protein composed of three identical peptide chains (monomers).
The peptide chain of the type V collagen consists of 2 alpha 1 chains and 1 alpha 2 chains or 3 alpha 1 chains, and 3 assembly forms exist. Type v collagen is distributed around cells and type i collagen, and serves as a bridge between the basement membrane and connective tissue.
The type XI collagen is heterotrimer, its composition is alpha 1 (XI) alpha 2 (XI) alpha 3 (XI), type XI collagen is micro component of cartilage, plays an important role in formation of cartilage collagen fiber and composition of cartilage matrix, and is often coexistent with type II collagen.
The oligopeptide is collagen obtained by hydrolysis or enzymolysis, the molecular weight section is generally below 1000 daltons, and the oligopeptide, oligopeptide or small molecular active peptide is also called small peptide, and generally consists of 4-10 amino acids.
In a preferred embodiment of the present invention, the hyaluronic acid or a salt thereof is 1 to 100 parts by weight, preferably 10 to 100 parts by weight, and more preferably 50 to 100 parts by weight;
the collagen is 100-10000 parts, preferably 1000-10000 parts, more preferably 5000-10000 parts;
the aminobutyric acid is 1 to 100 parts, preferably 10 to 100 parts, and more preferably 50 to 100 parts.
For example, the hyaluronic acid or salt thereof may be 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 10 parts, 50 parts, 100 parts, etc., in parts by weight;
the collagen may be 100 parts, 200 parts, 500 parts, 1000 parts, 1500 parts, 2000 parts, 2500 parts, 3000 parts, 3500 parts, 4000 parts, 4500 parts, 5000 parts, 5500 parts, 6000 parts, 6500 parts, 7000 parts, 7500 parts, 8000 parts, 8500 parts, 9000 parts, 9500 parts, 10000 parts, etc.;
the aminobutyric acid may be 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 15 parts, 20 parts, 30 parts, 40 parts, 50 parts, 60 parts, 70 parts, 80 parts, 90 parts, 100 parts, etc.
For the above-mentioned composition, when 1 to 100 parts, preferably 10 to 100 parts, more preferably 50 to 100 parts of hyaluronic acid or a salt thereof is used, 100 to 10000 parts, preferably 1000 to 10000 parts, more preferably 5000 to 10000 parts of collagen and 1 to 100 parts, preferably 10 to 100 parts, more preferably 50 to 100 parts of aminobutyric acid are added.
In a preferred embodiment of the present invention, wherein the hyaluronic acid or salt thereof has a molecular weight of 10k-1000kDa, preferably 10k-100kDa or 200k-800kDa, further preferably 30k-50kDa or 200k-400kDa.
For example, the hyaluronic acid or salt thereof may have a molecular weight of 10kDa, 20kDa, 30kDa, 40kDa, 50kDa, 60kDa, 70kDa, 80kDa, 90kDa, 100kDa, 150kDa, 200kDa, 250kDa, 300kDa, 400kDa, 500kDa, 600kDa, 700kDa, 800kDa, 900kDa, 1000kDa, etc.
In a preferred embodiment of the invention, the collagen has a molecular weight of 200-10000Da, preferably 300-5000Da, more preferably 500-2000Da.
The molecular weight of the collagen refers to the weight average molecular weight.
The molecular weight of the hyaluronic acid or salt thereof refers to the weight average molecular weight.
For example, the molecular weight of the collagen may be 200Da, 300Da, 400Da, 500Da, 600Da, 800Da, 1000Da, 1500Da, 2000Da, 2500Da, 3000Da, 3500Da, 4000Da, 4500Da, 5000Da, 6000Da, 7000Da, 8000Da, 9000Da, 10000Da, etc.
In a preferred embodiment of the present invention, wherein the composition consists of hyaluronic acid or a salt thereof, collagen and aminobutyric acid.
The composition provided by the invention can play a role in synergy and mutual promotion due to the use of the aminobutyric acid as the accelerator, and can reduce the dosage of hyaluronic acid and collagen on the premise of keeping the original active performance, reduce the cost and reduce the risk caused by too high dosage.
The invention provides a product, which comprises the composition, wherein the composition accounts for 0.1-10% of the product by mass percent, and preferably 1-5% of the product by mass percent.
For example, the composition is 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, etc., by mass percent of the product.
In a preferred embodiment of the present invention, wherein the article is a food, cosmetic or pharmaceutical product.
In a preferred embodiment of the present invention, the product further comprises an auxiliary material, preferably, an auxiliary material acceptable in food, cosmetic or pharmaceutical.
The present invention is not limited in any way, and may be determined as needed, and for example, the auxiliary materials may be milk powder, vegetable edible oil, edible colorant, preservative, stabilizer, thickener, emulsifier, etc.
In a preferred embodiment of the present invention, wherein the food is a health food.
The invention provides the application of the composition in the fields of food, cosmetics or medicines.
In a preferred embodiment of the present invention, wherein the food is a health food.
According to the composition disclosed by the invention, the hyaluronic acid and the collagen can promote the self synthesis of substances, and the aminobutyric acid is used as the promoter, so that the respective synthesis of the hyaluronic acid and the collagen can be promoted, the composition disclosed by the invention not only can play a role in synergy while keeping the respective efficacy effects, but also can double promote the synthesis efficiency of the hyaluronic acid and the collagen, thereby achieving the effect of reducing and enhancing the efficiency, reducing the cost and the use risk, expanding the application range and the safety, and having good application prospects in the fields of foods, cosmetics or medicines.
Examples
The materials used in the test and the test methods are described generally and/or specifically in the examples which follow,% represents wt%, i.e. weight percent, unless otherwise specified. The reagents or apparatus used were conventional reagent products commercially available from Hua Xi Biotech Inc., without the manufacturer's knowledge,
type i collagen is supplied by Shanghai Corp industries Inc.,
aminobutyric acid was obtained from Hua Xi Biotech Co., ltd. (purity > 98%)
Human skin fibroblasts were supplied by the Beijing Beidou Naviet Union Biotechnology institute,
DMEM high sugar medium was supplied by Gibco,
the enzyme-linked immunosorbent assay is provided by TECAN.
Examples
The hyaluronic acid or its salt with different molecular weight, collagen with different amount and aminobutyric acid are mixed to obtain the composition, wherein the molecular weight of hyaluronic acid, the molecular weight of collagen and the dosage are shown in table 1 and table 2.
Comparative example
Hyaluronic acid or a salt thereof having a different molecular weight and collagen having a different molecular weight or hyaluronic acid or a salt thereof having a different molecular weight and aminobutyric acid or collagen having the same amount and aminobutyric acid were mixed in the same manner as in example 1 to obtain a mixture, wherein the molecular weight of hyaluronic acid, the molecular weight of collagen and the amount thereof are shown in tables 1 and 2.
TABLE 1 cell experiments component tables of different molecular weights and different amounts
TABLE 2 composition table for animal experiments with different molecular weights and different amounts
Note that: the gastric lavage dose was obtained by converting the body surface area of human and mouse by converting the dose of table 1.
Experimental example 1 skin fibroblast proliferation experiment
The skin fibroblast proliferation experiment adopts an MTT method to respectively measure the influence of the combination of two components, the three components and the collagen in the aminobutyric acid, the hyaluronic acid and the collagen on the proliferation rate of the skin fibroblast, and whether the skin fibroblast has a synergistic effect is examined.
Fibroblast culture: human skin fibroblasts were inoculated into DMEM high sugar medium containing 10% fetal bovine serum, 37 ℃,5% co 2 Culturing in a cell incubator for 24 hours, after the cells are approximately 80% fused, discarding the old culture medium, washing twice with PBS, adding a digestive liquid containing 0.25% trypsin and 0.02% EDTA for digestion, observing under an inverted microscope, sucking or pouring out the digestive liquid after the cells are retracted to round the protrusions or the cell gaps are enlarged, adding a proper amount of culture medium, repeatedly blowing the digested cells to remove walls and disperse, and passaging the cell suspension according to a ratio of 1:3.
Fibroblast cells were seeded into 96-well cell culture plates at a density of 1X 10 5 Adding 100 μl of DMEM medium containing 10% foetal calf serum per well per ml, culturing at 37deg.C, and 5% CO 2 The cells were cultured in conditioned cell culture boxes for 24 hours.
Adding the medicine: after 24 hours of conventional culture, the old culture broth was discarded, 100. Mu.L of the sample was added as in Table 1, the negative control group (control) was added with an equal amount of serum-free culture broth, the blank group was cell-free, and only serum-free culture broth was added. 4 concentration levels per sample, 6 parallel wells per level.
Cell proliferation rate assay: after the continuous culture for 24 hours, the relative proliferation rate of the cells is detected by adopting a WST-1 method, the old culture solution is discarded, 100 mu L of serum-free culture solution and 10 mu L of WST-1 are added into each hole, the mixture is placed into a cell culture box for continuous incubation for 2 to 4 hours, and the absorbance is measured at the wavelength of 450nm by using an ELISA.
TABLE 3 Effect of compositions on fibroblast proliferation Rate
/>
As can be seen from the data in Table 3, the optimal molecular weight of hyaluronic acid for fibroblast proliferation is 30kDa-50kDa and 200kDa-400kDa, and the optimal dosage is 100mg/dl; the optimal molecular weight of collagen for fibroblast proliferation is 500Da and 2000Da, the optimal dosage is 10000mg/dl, and the optimal dosage of aminobutyric acid is 100mg/dl. Hyaluronic acid and collagen, collagen and aminobutyric acid, and hyaluronic acid and aminobutyric acid are combined in pairs to have a synergistic effect, and after the aminobutyric acid component is added, the cell proliferation promoting effect of hyaluronic acid and collagen can be obviously enhanced. The three are combined, hyaluronic acid: collagen: aminobutyric acid in (50-100): (5000-10000): in the interval (50-100), the fibroblast proliferation effect is optimal.
Experimental example 2 animal experiment
Experimental principle: the composition was orally administered to photoaging model mice, and the changes in the content of hyaluronic acid and collagen in the skin of photoaging mice after one month were measured.
The experimental animals were Kunming mice 18-20g, male and female halves, SPF grade.
Photo-aging and molding: the mice for experiments were anesthetized with 10% chloral hydrate (0.3 mL/100 g) and fixed on a treatment table, the hairs on the backs of the mice were shaved off with a razor blade to expose the back skin sufficiently, the hairs were shaved 1 time every other day, the mice for the group with chronic UV injury were fixed in a self-made holder, the back illumination position of the mice was determined, the mice for the experiment group were placed at 30cm under an ultraviolet light therapeutic apparatus, and the UVB intensity was 0.45mW/cm 2 UVA intensity 6.7mW/cm 2 The minimum erythema is UVB0.07J/cm 2 UVA was defined as 10 times UVB, i.e. 0.7J/cm 2 According to the formula: irradiation time = irradiation dose/irradiation intensity, 0.5 erythema dose increased weekly, 1 day, 5 days weekly for 4 weeks; the control mice and the UV injury mice are fed with the same feed in the same environment.
Experimental grouping: the experiments were divided into a blank control group, a model control group and a model administration group, wherein 10 animals and a half were respectively administered with the compositions shown in table 2, the blank control group and the model control group were synchronously filled with tap water, and the stomach filling administration and the modeling of the experiment group were simultaneously performed.
Experimental determination: after one month of mold administration, mice were sacrificed by cervical removal, the back was placed on a treatment plate, and after disinfection with alcohol, skin tissue of appropriate size was taken and placed in an EP tube, homogenized, centrifuged to obtain supernatant, and the hyaluronic acid and collagen contents in the skin of mice were measured according to the hyaluronic acid test kit and collagen test kit (TSZ) instructions, and the results are shown in table 4.
Table 4 effect of composition on hyaluronic acid content and collagen content in photoaging model skin
/>
As can be seen from the data in table 4, with the blank control group and the model control group as references, the synthesis of hyaluronic acid and collagen in the skin of normal mice can be significantly improved, the aging effect of light and ultraviolet on the mice can be reversed, and the content of hyaluronic acid and collagen in the skin can be improved; the three are applied together, and the synthesis promotion effect is positively correlated with the increase of the dosage. As is clear from examples and comparative examples, the low dose of hyaluronic acid and collagen added with a certain dose of aminobutyric acid has an equivalent or higher effect than the high dose of hyaluronic acid and aminobutyric acid, so that aminobutyric acid can reduce the cost and use risk of hyaluronic acid and collagen, and expand the application range and safety.
In conclusion, the composition disclosed by the invention takes the aminobutyric acid as the accelerator, enhances the synergistic effect of the hyaluronic acid and the collagen, not only can play a role in synergistic effect and mutual promotion, but also can reduce the dosage of the hyaluronic acid and the collagen on the premise of keeping the original active performance, reduce the cost and reduce the risk caused by too high dosage.
The above description is only a preferred embodiment of the present invention, and is not intended to limit the invention in any way, and any person skilled in the art may make modifications or alterations to the disclosed technical content to the equivalent embodiments. However, any simple modification, equivalent variation and variation of the above embodiments according to the technical substance of the present invention still fall within the protection scope of the technical solution of the present invention.
Claims (14)
1. A composition comprising hyaluronic acid or a salt thereof, collagen, and aminobutyric acid;
the hyaluronic acid or the salt thereof is 50-100 parts by weight;
5000-10000 parts of collagen;
50-100 parts of aminobutyric acid;
the collagen is selected from type I collagen or oligopeptide thereof, type II collagen or oligopeptide thereof, type III collagen or oligopeptide thereof, type V collagen or oligopeptide thereof, type XI collagen or oligopeptide thereof;
the molecular weight of the hyaluronic acid or the salt thereof is 10k-100kDa or 200k-800kDa;
the molecular weight of the collagen is 300-5000Da.
2. The composition of claim 1, wherein the hyaluronic acid or salt thereof is selected from hyaluronic acid, sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, calcium hyaluronate, magnesium hyaluronate, acetylated hyaluronic acid, thiolated hyaluronic acid, or lightly crosslinked hyaluronic acid.
3. The composition of claim 1, wherein the hyaluronic acid or salt thereof is sodium hyaluronate.
4. The composition of claim 1, wherein the collagen is type i collagen.
5. The composition of any one of claims 1-4, wherein the hyaluronic acid or salt thereof has a molecular weight of 30k-50kDa or 200k-400kDa.
6. The composition of any one of claims 1-4, wherein the collagen has a molecular weight of 500-2000Da.
7. An article comprising the composition of any one of claims 1-6, wherein the composition is 0.1-10% by mass percent of the article.
8. The article of claim 7, wherein the composition is 1-5% by mass of the article.
9. The article of claim 7, wherein the article is a food, cosmetic, or pharmaceutical product.
10. The article of any of claims 7-9, wherein the article further comprises an adjunct.
11. The article of claim 10, wherein the adjunct is a food, cosmetic or pharmaceutical acceptable adjunct.
12. The article of claim 11, wherein the food product is a health food product.
13. Use of a composition according to any one of claims 1 to 6 for the preparation of a food, cosmetic or pharmaceutical product.
14. The use according to claim 13, wherein the food product is a health food product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110963198.3A CN113679046B (en) | 2021-08-20 | 2021-08-20 | Composition for promoting interaction of hyaluronic acid and collagen and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110963198.3A CN113679046B (en) | 2021-08-20 | 2021-08-20 | Composition for promoting interaction of hyaluronic acid and collagen and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113679046A CN113679046A (en) | 2021-11-23 |
| CN113679046B true CN113679046B (en) | 2024-03-08 |
Family
ID=78581145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110963198.3A Active CN113679046B (en) | 2021-08-20 | 2021-08-20 | Composition for promoting interaction of hyaluronic acid and collagen and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113679046B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306130A (en) * | 2022-01-10 | 2022-04-12 | 深圳市回春堂健康管理服务有限公司 | Composition for promoting interaction of collagen and hyaluronic acid and application thereof |
| CN115010949B (en) * | 2022-07-12 | 2024-02-13 | 华熙生物科技股份有限公司 | Penetration enhancer, skin care composition and cosmetic |
| WO2024140865A1 (en) * | 2022-12-28 | 2024-07-04 | 华熙生物科技股份有限公司 | USE OF γ-AMINOBUTYRIC ACID IN PREVENTING AND/OR AMELIORATING CELL DAMAGE CAUSED BY IRRITANT, AND METHOD |
| CN116370341A (en) * | 2023-04-24 | 2023-07-04 | 华熙生物科技股份有限公司 | Use, method and composition for inhibiting and/or slowing down decomposition of hyaluronic acid or salt thereof and/or maintaining hyaluronic acid or salt thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010053120A (en) * | 2008-07-28 | 2010-03-11 | Q P Corp | Skin improvement agent for oral, food containing the same, and method for improving skin |
| JP2011205907A (en) * | 2010-03-27 | 2011-10-20 | Nippon Menaade Keshohin Kk | Collagen peptide-containing beverage |
| CN103930560A (en) * | 2011-08-18 | 2014-07-16 | 赢创德固赛有限公司 | Method for producing 4-aminobutyric acid from algae |
| CN105362091A (en) * | 2015-12-16 | 2016-03-02 | 华熙福瑞达生物医药有限公司 | Composition containing gamma-aminobutyric acid and hyaluronic acid and application of same to cosmetics |
| CN110075006A (en) * | 2019-04-19 | 2019-08-02 | 华熙生物科技股份有限公司 | Promote the method for the solution compatibility of hyaluronic acid substance and typeⅡ Collagen and the composition containing both substances |
| CN112190503A (en) * | 2020-11-11 | 2021-01-08 | 华熙生物科技股份有限公司 | Hyaluronic acid composition with penetration promoting effect, preparation method and application thereof |
| CN112656713A (en) * | 2020-12-25 | 2021-04-16 | 华熙生物科技股份有限公司 | Cosmetic composition containing hyaluronic acid and/or derivatives thereof, and preparation method and application thereof |
| CN112890064A (en) * | 2021-02-22 | 2021-06-04 | 青岛元生肽健康产业有限公司 | Composite collagen peptide solid beverage and preparation method thereof |
| CN113017093A (en) * | 2021-04-13 | 2021-06-25 | 上海同济生物制品有限公司 | Composition with functions of maintaining beauty, keeping young and helping sleep and preparation method thereof |
| CN113133534A (en) * | 2020-01-20 | 2021-07-20 | 上海建华精细生物制品有限公司 | Tranquilizing and relieving sustained-release oral liquid and preparation method thereof |
-
2021
- 2021-08-20 CN CN202110963198.3A patent/CN113679046B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010053120A (en) * | 2008-07-28 | 2010-03-11 | Q P Corp | Skin improvement agent for oral, food containing the same, and method for improving skin |
| JP2011205907A (en) * | 2010-03-27 | 2011-10-20 | Nippon Menaade Keshohin Kk | Collagen peptide-containing beverage |
| CN103930560A (en) * | 2011-08-18 | 2014-07-16 | 赢创德固赛有限公司 | Method for producing 4-aminobutyric acid from algae |
| CN105362091A (en) * | 2015-12-16 | 2016-03-02 | 华熙福瑞达生物医药有限公司 | Composition containing gamma-aminobutyric acid and hyaluronic acid and application of same to cosmetics |
| CN110075006A (en) * | 2019-04-19 | 2019-08-02 | 华熙生物科技股份有限公司 | Promote the method for the solution compatibility of hyaluronic acid substance and typeⅡ Collagen and the composition containing both substances |
| CN113133534A (en) * | 2020-01-20 | 2021-07-20 | 上海建华精细生物制品有限公司 | Tranquilizing and relieving sustained-release oral liquid and preparation method thereof |
| CN112190503A (en) * | 2020-11-11 | 2021-01-08 | 华熙生物科技股份有限公司 | Hyaluronic acid composition with penetration promoting effect, preparation method and application thereof |
| CN112656713A (en) * | 2020-12-25 | 2021-04-16 | 华熙生物科技股份有限公司 | Cosmetic composition containing hyaluronic acid and/or derivatives thereof, and preparation method and application thereof |
| CN112890064A (en) * | 2021-02-22 | 2021-06-04 | 青岛元生肽健康产业有限公司 | Composite collagen peptide solid beverage and preparation method thereof |
| CN113017093A (en) * | 2021-04-13 | 2021-06-25 | 上海同济生物制品有限公司 | Composition with functions of maintaining beauty, keeping young and helping sleep and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113679046A (en) | 2021-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113679046B (en) | Composition for promoting interaction of hyaluronic acid and collagen and application thereof | |
| JP5894341B2 (en) | Composition comprising collagen peptide, elastin peptide and proteoglycan | |
| US9347081B2 (en) | Cartilage product | |
| EP3003264A1 (en) | Combination of active agents for treating skin aging | |
| JP2000201649A (en) | Dermal metabolism accelerator and functional food | |
| CN115381733A (en) | Anti-aging composition for promoting collagen effect and application thereof | |
| CN114306130A (en) | Composition for promoting interaction of collagen and hyaluronic acid and application thereof | |
| WO2020022131A1 (en) | Anti-aging agent for skin and anti-aging-related gene expression regulator | |
| JP3510861B2 (en) | Beauty food | |
| JPWO2015015816A1 (en) | Fibroblast activator | |
| KR101305274B1 (en) | Composition for improving collagen synthesis | |
| KR101247511B1 (en) | Low molecular weight chondroitin sulfate hydrolysate preparation method and the cosmetic composition containing the same | |
| CN117137146A (en) | Raw material composition for enhancing skin elasticity and preparation method thereof | |
| KR101218898B1 (en) | Composition for improving collagen synthesis | |
| KR20180085198A (en) | Composition for improving skin and health food comprising the same | |
| CN109464651A (en) | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine | |
| JPWO2016129174A1 (en) | Hyaluronic acid production promoter | |
| CN101912349B (en) | Application of water soluble vitamin E for preparing transdermal enhancer and cosmetics prepared therefrom | |
| CN108289809A (en) | Stimulate hyaluronic acid synthetic method | |
| CN111067845A (en) | Natural plant multi-effect repair mask and preparation method thereof | |
| TWI576117B (en) | Hyaluronic acid production promoter | |
| CN116195690A (en) | Universal hair-beautifying nutritional paste for dogs and cats and preparation method thereof | |
| JPWO2015015815A1 (en) | Fibroblast activator | |
| CN109965104A (en) | A kind of composition and its preparation method and application containing Sodium Hyaluronate | |
| CN118216674A (en) | Anti-aging composition for promoting collagen effect and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |